Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Durvalumab in Metastatic TNBC
NCT03544125Phase 1Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib and durvalumab in triple-negative breast cancer (TNBC), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Proportion of completion of Clinical Laboratory Improvement Act (CLIA) analytics on pre-treatment biopsy at Day 28. Started May 2018; status: completed.
02
Drugs
olaparibdurvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03544125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03544125.